NEUP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

3 Analyst Rating

Wall Street analysts forecast NEUP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEUP is 14.43 USD with a low forecast of 2.30 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 3.830

Low

2.30

Averages

14.43

High

21.00

Current: 3.830

Low

2.30

Averages

14.43

High

21.00

H.C. Wainwright

Buy

downgrade

$21 -> $7

2025-12-05

Reason

H.C. Wainwright

Price Target

$21 -> $7

2025-12-05

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Neuphoria Therapeutics to $7 from $21 and keeps a Buy rating on the shares. The firm says the company is "caught between a rock and a hard place right now." With the Phase 3 social anxiety disorder failure, Neuphoria's risk profile "has increased significantly," the anlayst tells investors in a research note. However, the firm says the positive Phase 2b post-traumatic stress disorder data still provides value to the company.

Lucid Capital

Elemer Piros

Buy -> Neutral

downgrade

$81

2025-10-21

Reason

Lucid Capital

Elemer Piros

Price Target

$81

2025-10-21

downgrade

Buy -> Neutral

Reason

Lucid Capital analyst Elemer Piros downgraded Neuphoria Therapeutics to Neutral from Buy with a price target of $2.30, down from $81, after the Phase 3 AFFIRM-1 trial of BNC210 for the acute treatment of social anxiety disorder failed to meet its primary endpoint. The study also did not show statistically significant results across secondary endpoints, the analyst tells investors in a research note.

Maxim

Buy

maintain

$18 -> $35

2025-09-11

Reason

Maxim

Price Target

$18 -> $35

2025-09-11

maintain

Buy

Reason

Maxim raised the firm's price target on Neuphoria Therapeutics to $35 from $18 and keeps a Buy rating on the shares. The firm cites the company's announcement that enrollment has been completed in the Phase 3 'AFFIRM-1' study of BNC210 in social anxiety disorder, positioning for a top-line data readout in early Q4, the analyst tells investors in a research note. Maxim adds that it continues to believe the risk/reward is favorable and as such, lowers the discount rate in its valuation model to 30% from 35%, which raises its price target.

Lucid Capital

NULL

Buy

initiated

$81

2025-09-04

Reason

Lucid Capital

Price Target

$81

2025-09-04

initiated

NULL

Buy

Reason

Lucid Capital initiated coverage of Neuphoria Therapeutics with a Buy rating and $81 price target. The company is developing BNC210 to treat social anxiety disorder episodically, the analyst tells investors in a research note. The firm says that with no agent approved for the acute treatment of anxiety attacks in a social situation, BNC210 offers a "best- and first-in-class" profile.

Valuation Metrics

The current forward P/E ratio for Neuphoria Therapeutics Inc (NEUP.O) is -1.24, compared to its 5-year average forward P/E of -1.84. For a more detailed relative valuation and DCF analysis to assess Neuphoria Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.84

Current PE

-1.24

Overvalued PE

-0.70

Undervalued PE

-2.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.14

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.18

Undervalued EV/EBITDA

-0.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.36

Current PS

0.00

Overvalued PS

1.38

Undervalued PS

-0.66

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NEUP News & Events

Events Timeline

No data

News

9.0

12-08Newsfilter

Neuphoria Urges Shareholders to Support Director Nominees for Maximum Value

4.5

10-24Benzinga

Nasdaq Rises 1%; Procter & Gamble Reports Positive Earnings

4.5

10-21TipRanks

Tuesday's Major Stock Market Highlights: Morning News Summary!

People Also Watch

Frequently Asked Questions

What is Neuphoria Therapeutics Inc (NEUP) stock price today?

The current price of NEUP is 3.83 USD — it has decreased -6.13 % in the last trading day.

What is Neuphoria Therapeutics Inc (NEUP)'s business?

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

What is the price predicton of NEUP Stock?

What is Neuphoria Therapeutics Inc (NEUP)'s revenue for the last quarter?

Neuphoria Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Neuphoria Therapeutics Inc (NEUP)'s earnings per share (EPS) for the last quarter?

Neuphoria Therapeutics Inc. EPS for the last quarter amounts to -4.41 USD, decreased % YoY.

What changes have occurred in the market's expectations for Neuphoria Therapeutics Inc (NEUP)'s fundamentals?

The market is revising No Change the revenue expectations for Neuphoria Therapeutics Inc. (NEUP) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -69.38%.

How many employees does Neuphoria Therapeutics Inc (NEUP). have?

Neuphoria Therapeutics Inc (NEUP) has 7 emplpoyees as of December 16 2025.

What is Neuphoria Therapeutics Inc (NEUP) market cap?

Today NEUP has the market capitalization of 20.60M USD.